-

Forbes Names Zoetis One of America’s Best Midsize Employers

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS), the global leader in animal health, today announced that it has been named one of America’s Best Midsize Employers by Forbes Magazine for the fifth time.

“At Zoetis, our colleagues drive our success and shape our reputation as a top employer,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Global Operations. “We continue to build a diverse and inclusive culture - based on our Core Beliefs – where everyone can thrive, both personally and professionally. We are proud to consistently be recognized by Forbes as one of America’s Best Midsize Employers, and we thank our colleagues for recommending Zoetis as a great place to work.”

Forbes determined its America’s Best Employers list based on an independent survey among a sample of 50,000 American employees working for companies with at least 1,000 people in their U.S. operations. The willingness to recommend one's own employer was used as the most important factor in the assessment. The employees were consulted anonymously through online access panels which allowed them to express their opinions. Visit Forbes.com for more details about the list of America’s Best Midsize Employers.

Award-Winning Culture

Zoetis has consistently been recognized as a great place to work. The company has been named among the Top Companies for Working Mothers for the past seven years, as well as a Top Company for Executive Women for three years in a row. Most recently, Zoetis received a score of 100 percent on the Human Rights Campaign Foundation’s 2021 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ workplace equality.

Learn More

For more information about Zoetis, including career opportunities, our commitment to Diversity, Equity and Inclusion, and our award-winning culture, visit https://careers.zoetis.com/.

About Zoetis

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses.

Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees. For more information, visit www.zoetis.com.

ZTS-COR

Contacts

Media Contacts:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Summary
Zoetis has been named one of America’s Best Midsize Employers by Forbes Magazine for the fifth time.
Release Versions
$Cashtags

Contacts

Media Contacts:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Social Media Profiles
More News From Zoetis Inc.

Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET. Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be ava...

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax, commonly called New World screwworm (NWS), feed on living tissues, such as open wounds, of animals including livestock, wildlife and pets, and can inflict da...

Zoetis Announces Second Quarter 2026 Results

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the second quarter of 2026. The company reported revenue of $2.5 billion for the second quarter of 2026, flat compared with the second quarter of 2025, decreasing 1% on an organic operational1 basis. Net income for the second quarter of 2026 was $691 million, or $1.65 per diluted share, decreasing 5% and growing 1%, respectively, on a reported basis. Adj...
Back to Newsroom